Hu Henglong, Zhang Jiaqiao, Lu Yuchao, Zhang Zongbiao, Qin Baolong, Gao Hongbin, Wang Yufeng, Zhu Jianning, Wang Qing, Zhu Yunpeng, Xun Yang, Wang Shaogang
Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430030, China.
Nutrients. 2017 Mar 18;9(3):301. doi: 10.3390/nu9030301.
Many studies compared the serum/plasma 1,25 dihydroxyvitamin D₃ (1,25(OH)₂D) and 25 hydroxyvitamin D₃ (25(OH)D) between people with and without nephrolithiasis, and their results were conflicting. After systematically searching PubMed, Web of Science, The Cochrane Library, CNKI, and the Wanfang Database, we conducted a meta-analysis. Thirty-two observational studies involving 23,228 participants were included. Meta-analysis of these studies showed that of stone formers (SFs), calcium SFs had significantly higher concentrations of 1,25(OH)₂D (weighted mean difference (WMD), 10.19 pg/mL; 95% confidence interval (CI), 4.31-16.07; = 0.0007 and WMD, 11.28 pg/mL; 95% CI, 4.07-18.50; = 0.002, respectively) than non-stone formers, while the levels of 25(OH)D (WMD, 0.88 ng/mL; 95% CI, -1.04-2.80; = 0.37 and WMD, -0.63 ng/mL; 95% CI, -2.72-1.47; = 0.56, respectively) are similar. Compared with controls and normocalciuria SFs, hypercalciuria SFs had increased circulating 1,25(OH)₂D (WMD, 9.41 pg/mL; 95% CI, 0.15-18.67; = 0.05 and WMD, 2.75 pg/mL; 95% CI, -0.20-5.69; = 0.07, respectively) and markedly higher 25(OH)D (WMD, 5.02 ng/mL; 95% CI, 0.99-9.06; = 0.01 and WMD, 5.02 ng/mL; 95% CI, 2.14-7.90; = 0.0006, respectively). Normocalciuria SFs had elevated 1,25(OH)₂D level (WMD, 6.85 pg/mL; 95% CI, -5.00-18.71; = 0.26) and comparable 25(OH)D (WMD, 0.94 ng/mL; 95% CI, -3.55-5.43; = 0.68). Sensitivity analysis generated similar results. Current evidence suggests that increased circulating 1,25(OH)₂D is associated with urinary stones and a higher level of circulating 25(OH)D is significantly associated with hypercalciuria urolithiasis. Further studies are still needed to reconfirm and clarify the role of vitamin D in the pathogenesis of stones.
许多研究比较了有和没有肾结石的人群之间血清/血浆1,25 - 二羟维生素D₃(1,25(OH)₂D)和25 - 羟维生素D₃(25(OH)D)的水平,其结果相互矛盾。在系统检索了PubMed、科学网、考克兰图书馆、中国知网和万方数据库后,我们进行了一项荟萃分析。纳入了32项涉及23228名参与者的观察性研究。对这些研究的荟萃分析表明,在结石形成者(SFs)中,钙结石形成者的1,25(OH)₂D浓度显著高于非结石形成者(加权平均差(WMD)分别为10.19 pg/mL;95%置信区间(CI)为4.31 - 16.07;P = 0.0007和WMD为11.28 pg/mL;95% CI为4.07 - 18.50;P = 0.002),而25(OH)D水平(WMD分别为0.88 ng/mL;95% CI为 - 1.04 - 2.80;P = 0.37和WMD为 - 0.63 ng/mL;95% CI为 - 2.72 - 1.47;P = 0.56)相似。与对照组和正常钙尿性结石形成者相比,高钙尿性结石形成者的循环1,25(OH)₂D升高(WMD分别为9.41 pg/mL;95% CI为0.15 - 18.67;P = 0.05和WMD为2.75 pg/mL;95% CI为 - 0.20 - 5.69;P = 0.07),且25(OH)D显著更高(WMD分别为5.02 ng/mL;95% CI为0.99 - 9.06;P = 0.01和WMD为5.02 ng/mL;95% CI为2.14 - 7.90;P = 0.0006)。正常钙尿性结石形成者的1,25(OH)₂D水平升高(WMD为6.85 pg/mL;95% CI为 - 5.00 - 18.71;P = 0.26),25(OH)D水平相当(WMD为0.94 ng/mL;95% CI为 - 3.55 - 5.43;P = 0.68)。敏感性分析产生了相似的结果。目前的证据表明,循环1,25(OH)₂D升高与尿路结石有关,而循环25(OH)D水平升高与高钙尿性尿路结石显著相关。仍需要进一步的研究来再次确认和阐明维生素D在结石发病机制中的作用。